echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > CStone Announces Presentation of Multispecific Antibody Candidate Therapy CS2006/NM21-1480 Study Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting

    CStone Announces Presentation of Multispecific Antibody Candidate Therapy CS2006/NM21-1480 Study Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting

    • Last Update: 2022-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>


    • Research Field: Therapeutic Antibodies
    • Date: April 12, 2022, 9:00am-12:30pm ET
    • Report form: electronic poster
    • Title: Dose Selection Study and Combination Administration Strategy of PD-L1/4-1BB/HSA Trispecific Clinical Candidate NM21-1480 Based on MATCH3 Form
    • Speaker: Dr.


      Compared with other PD-L1/4-1BB bispecific candidate antibodies, CS2006/NM21-1480's unique monovalent structure design and ultra-high affinity for PD-L1 will enable dual effects of PD-L1 and 4-1BB in tumor areas maximizing the potential to deliver broader and longer-lasting therapeutic remission to patients while avoiding systemic toxicity


      Dr.


      CS2006/NM21-1480 is designed and developed by CStone's partner Numab Therapeutics (Numab for short) based on its unique λcap™ technology and MATCH™ platform.


      About CStone

      CStone Pharmaceuticals (SEHK: 2616) is a biopharmaceutical company focused on the research, development and commercialization of innovative immuno-oncology and precision medicines to meet the high medical needs of cancer patients in China and around the world


      To learn more about CStone, please visit:.


      Forward-Looking Statements

      Forward-looking statements made herein relate only to events or information as of the date on which they are made


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.